The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche/Genentech
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).
 
Antonio Llombart-Cussac
Honoraria - AstraZeneca; Lilly; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Lilly; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Piqur; Puma Biotechnology; Roche/Genentech
 
Meritxell Bellet
Speakers' Bureau - AstraZeneca
 
Pilar Zamora
No Relationships to Disclose
 
Manuel Ruiz
No Relationships to Disclose
 
Joseph Gligorov
Consulting or Advisory Role - Eisai; Pfizer; Roche/Genentech; Teva
Speakers' Bureau - Genomic Health
 
Serena Di Cosimo
No Relationships to Disclose
 
Peter Schmid
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Roche/Genentech
Research Funding - Astellas Pharma; AstraZeneca; Genentech
 
Shaheenah Dawood
No Relationships to Disclose
 
Henri Roche
No Relationships to Disclose
 
Frederic Marme
No Relationships to Disclose
 
Elena Aguirre
No Relationships to Disclose
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Roche/Genentech
Consulting or Advisory Role - Celgene; Roche/Genentech